Alumis Inc. Common Stock

ALMS XNAS • PHARMACEUTICAL PREPARATIONS

Historical Short Interest Share

Chase Ink Business Preferred®

Earn Up to 150K Bonus Points

Transfer points to 14+ airline & hotel partners. Up to 40% upgrade value on first class travel. $95/yr.

Apply Now

Market Cap

2.6B

Short interest (May 15)

8.9%

Net Short (Jun 03 ): 0.0%

Borrow Fee

0.43%

↑ 1.1%

Available Shares

↓ 29.5%

Price Chart

Company Overview

Alumis Inc is a clinical-stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 ("TYK2") inhibitors: envudeucitinib ("envu"), an allosteric TYK2 inhibitor for the treatment of PsO and SLE; and A-005, a central nervous system ("CNS") penetrant allosteric TYK2 inhibitor, to offer the therapeutic benefit of TYK2 inhibition within the CNS for a broad range of neuroinflammatory and neurodegenerative diseases.

Company Info

Exchange: NASDAQ

Industry: PHARMACEUTICAL PREPARATIONS

CIK: 0001847367

Asset Type: CS

Market Data

Market Cap: $2,554,939,279

Employees: 227

Status: Active

Short Interest

Current Borrow Fee 0.43%

Range: 0.41% - 0.43%

Available Shares 1M

Range: 900K - 950K

Recent Changes

Fee Change: ↑ 2.1%

Available Change: ↑ 20.0%

Quick Actions

View Dilution Chart

Add to Watchlist Set Price Alert View Options Chain

Investment Risk

This is not financial advice. All investments carry risk. Do your own research before making investment decisions.

Weekly Research

Get Weekly Super Stonk Alerts

Never miss a squeeze opportunity. Get our weekly analysis of high short interest stocks, AI-discovered gems, and dilution warnings delivered to your inbox.

No spam • Unsubscribe anytime